How much does vepotuzumab (POLIVY) cost?

Vepotuzumab (POLIVY) is a prescription medicine used with other medicines (rituximab products, cyclophosphamide, doxorubicin, and prednisone) for people with moderate-to-high-risk diffuse large B-cell lymphoma ( As the first treatment of adults with DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL), it may also be used to treat adults with DLBCL that has progressed after at least 2 prior lines of therapy.

Vepotuzumab is a CD79b-directed antibody-drug conjugate that delivers the antimitotic agent monomethylauristatin E (MMAE) to cancer cells. The drug consists of three components: a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab) and a protease-cleavable linker that covalently links MMAE to polatuzumab. Most importantly, CD79b has received increasing attention as a promising therapeutic target because of its important role in BCR expression, trafficking, and functions such as B cell proliferation and differentiation.

Vepotolizumab's patent medicine has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. It is an injectable preparation. The price of 30 mg per box may be around RMB 10,000. The price of the Hong Kong version of 140 mg per box may be around RMB 60,000 (the price may fluctuate due to exchange rates) overseas. The price of the European version of vepotuzumab on the market, Specifications140 mg per box, may be around 90,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs are basically the same as those of foreign original drugs, and they are expensive. There are currently no generic versions of vepotuzumab on the market.